Skip to main content

Table 3 Summary of the most common adverse events

From: Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR

 

PCG arm (N = 43) (%)

PC arm (N = 43) (%)

P-value for all grade AE

All grade

Gr 3

Gr 4

Gr 5

All grade

Gr 3

Gr 4

Gr 5

Patients with ≥ 1 AE (Gr3/4/5)

10 (23)

   

12 (28)

   

0.244

aRash

27 (63)

   

2 (5)

   

<0.001

aPruritis

13 (37)

   

4 (9)

   

0.012

Myalgia

25 (58)

   

28 (65)

   

0.506

Neuropathy

21 (49)

   

25 (58)

   

0.387

Alopecia

24 (56)

   

21 (49)

   

0.517

Anorexia

15 (35)

   

18 (42)

   

0.506

Cough

16 (37)

   

11 (26)

   

0.245

Nausea

13 (30)

   

8 (19)

   

0.209

Fatigue

10 (23)

   

10 (23)

   

1.000

Dyspepsia

6 (14)

   

7 (16)

   

0.763

Constipation

6 (14)

   

6 (14)

   

1.000

Diarrhea

5 (12)

   

5 (12)

1 (2)

  

1.000

Chest pain

5 (12)

   

5 (12)

   

1.000

General weakness

5 (12)

1 (2)

  

5 (12)

   

1.000

Infection

6 (14)

4 (9)

 

2 (5)

3 (7)

3 (7)

  

0.483

TE event

1 (2)

   

2 (5)

 

1 (2)

1 (2)

0.571

Neutropenia

10 (23)

 

2 (5)

 

7 (16)

3 (7)

1 (2)

 

0.660

Febrile neutropenia

0

   

1 (2)

   

1.000

Anemia

35 (81)

1 (2)

  

34 (79)

1 (2)

  

0.787

Thrombocytopenia

9 (21)

   

8 (19)

1 (2)

  

0.787

Leucopenia

6 (14)

2 (5)

  

6 (14)

 

1 (2)

 

1.000

Increased LFT

15 (35)

1 (2)

  

11 (26)

   

0.348

  1. AE adverse event; Gr grade; N number, LFT liver function test
  2. asignificant difference between two groups